Drug Profile
Research programme: nanomedicines - Pfizer/Merck & Co
Alternative Names: KSP Accurin™ - Pfizer/Merck & Co; KSP inhibitors - Pfizer/Merck & Co; PLK1 Accurin™ - Pfizer/Merck & Co; PLK1 inhibitors - Pfizer/Merck & CoLatest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator BIND Therapeutics; Merck & Co
- Developer Merck & Co; Pfizer
- Class
- Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer